Pages that link to "Q34083140"

The following pages link to Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial (Q34083140):

Displaying 25 items.

• Targeted therapy of gastrointestinal stromal tumours (Q26745633) (← links)
• Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions (Q26799387) (← links)
• Autoimmune-like hepatitis during masitinib therapy in an amyotrophic lateral sclerosis patient. (Q36085618) (← links)
• Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor (Q36125976) (← links)
• State of the Art in the Treatment of Gastrointestinal Stromal Tumors (Q36344557) (← links)
• Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics. (Q38323440) (← links)
• Heat-shock protein 90 (Hsp90) as anticancer target for drug discovery: an ample computational perspective (Q38469746) (← links)
• Masitinib for the treatment of mild to moderate Alzheimer's disease (Q38472067) (← links)
• Systemic therapy options for advanced gastrointestinal stromal tumors beyond first-line imatinib: a systematic review. (Q38527941) (← links)
• Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib (Q38627885) (← links)
• Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies (Q38925022) (← links)
• Therapeutic Strategies Under Development Targeting Inflammatory Mechanisms in Amyotrophic Lateral Sclerosis (Q39271545) (← links)
• Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib (Q44640459) (← links)
• Emerging drugs for the treatment of gastrointestinal stromal tumour (Q47355982) (← links)
• New targets and therapies for gastrointestinal stromal tumors (Q47432725) (← links)
• [Advanced gastrointestinal stromal tumors : What role does surgery currently play in multimodal concepts?]. (Q53121873) (← links)
• Contemporary Management of Metastatic Gastrointestinal Stromal Tumors: Systemic and Locoregional Approaches. (Q54863183) (← links)
• Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro. (Q55254546) (← links)
• Advances and Challenges on Management of Gastrointestinal Stromal Tumors. (Q55263134) (← links)
• New frontiers in the medical management of gastrointestinal stromal tumours. (Q64948703) (← links)
• Effects of masitinib compared with tadalafil for the treatment of monocrotaline-induced pulmonary arterial hypertension in rats (Q90822809) (← links)
• The Use of Molecular Subtypes for Precision Therapy of Recurrent and Metastatic Gastrointestinal Stromal Tumor (Q91789075) (← links)
• Detection of tyrosine kinase inhibitors-induced COX-2 expression in bladder cancer by fluorocoxib A (Q93187797) (← links)
• Tyrosine kinase inhibitor therapies for gastrointestinal stromal tumours (Q94347975) (← links)
• Gene duplication, rather than epigenetic changes, drives FGF4 overexpression in KIT/PDGFRA/SDH/RAS-P WT GIST (Q102075329) (← links)